ArticleFEBS open bio2026
Rapid screening of staphylokinase protein variants using an unpurified cell-free expression system.
Article in FEBS open bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Protein engineering approaches, including rational design and directed evolution, are essential for optimizing protein properties in biotechnology. However, their application is often limited by the need to experimentally characterize large numbers of variants. This is especially true for directed evolution, where selected candidates require heterologous expression and purification before functional testing. To reduce this bottleneck for staphylokinase, a fibrin-specific thrombolytic with therapeutic potential, we developed a rapid screening platform based on cell-free protein synthesis (CFPS) and a chromogenic plasminogen-activation assay. Activity rankings from crude CFPS mixtures closely matched those from purified proteins, showing that the method provides reliable functional readouts without purification. This CFPS-based workflow offers a fast, scalable, and efficient solution for early-stage screening of staphylokinase variants and can accelerate the identification of new thrombolytic candidates. The modularity of this method also allows its facile adjustment for other enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.